Used in pharmaceutical research as a key intermediate in the synthesis of immunomodulatory drugs, particularly in the development of analogs related to thalidomide and lenalidomide. It exhibits potential in targeting E3 ubiquitin ligase complexes, making it valuable in the design of proteolysis-targeting chimeras (PROTACs) for cancer therapy. Its structure supports binding to cereblon, a protein involved in protein degradation pathways, enabling selective degradation of disease-causing proteins. Also investigated for anti-inflammatory and anti-angiogenic properties in preclinical studies.